ArticleFrontiers in public health2025
The role of C-reactive protein in predicting all-cause mortality among Chinese arthritis patients: implications for public health education and promotion.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between adverse childhood experiences and accelerated aging of middle-aged and older Chinese: based on the China health and retirement longitudinal study.BMC public health · 2026Observational
- Effect of Small Dense Low-Density Lipoprotein Cholesterol Combined With High-Sensitivity C-Reactive Protein on Cardiometabolic Multimorbidity: A National Cohort Study.Clinical cardiology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Arthritis poses a significant public health challenge, contributing to increased healthcare resource utilization and reduced quality of life. C-reactive protein (CRP), a key inflammatory biomarker, plays a critical role in monitoring disease progression and guiding health promotion strategies. This study aims to investigate the association between CRP levels and all-cause mortality in Chinese arthritis patients, highlighting its implications for public health education and intervention programs. Methods: A prospective cohort study was conducted using data from the China Health and Retirement Longitudinal Study (CHARLS) from 2011 to 2020. Individuals diagnosed with arthritis in 2011 were included, with CRP levels as the primary exposure variable and mortality as the outcome of interest. Kaplan-Meier survival curves and Cox proportional hazards regression models were employed to assess the relationship between CRP levels and mortality risk, emphasizing the potential for targeted health education and promotion interventions. Results: A total of 3,413 participants were analyzed, with 87 deaths recorded during the 10-year follow-up period. Deceased individuals were older and exhibited higher levels of CRP, creatinine, and uric acid, alongside lower BMI, MET, eGFR, and HGB. Across three Cox regression models, elevated CRP levels (≥3 mg/L) were significantly associated with increased mortality risk [hazard ratio (HR) = 3.73 (2.23-6.23), HR = 3.00 (1.79-5.01), HR = 4.94 (1.77-13.78), respectively]. Kaplan-Meier survival curves further confirmed that arthritis patients with CRP levels ≥3 mg/L faced a markedly higher mortality risk. Conclusion: Elevated CRP levels are strongly associated with increased all-cause mortality in arthritis patients, underscoring the importance of integrating CRP monitoring into public health education and promotion strategies. Efforts to control inflammation and promote health literacy regarding arthritis management may improve survival outcomes and reduce the public health burden associated with arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.